Key terms
About IPHA
Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest IPHA news
Apr 16
2:36am ET
Buy Rating Affirmed for Innate Pharma Amidst Promising Platforms and Strategic Growth Potential
Apr 15
5:19am ET
Innate Pharma doses first patient in Sanofi-sponsored trial of SAR443579
Mar 26
4:45pm ET
Innate Pharma SA: A Balanced Hold Rating Amidst Clinical Setbacks and Cautious Optimism
Mar 22
6:27am ET
Innate Pharma: A Strong Buy on Promising Clinical Progress and Solid Financials
Mar 06
5:39am ET
Innate Pharma announces first patient dosed in IPH6501 trial
Feb 03
8:35pm ET
Innate Pharma SA (IPHYF) Receives a Hold from Kepler Capital
No recent press releases are available for IPHA
IPHA Financials
Key terms
Ad Feedback
IPHA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
IPHA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
